| Pharmaceutical Information |
| Drug Name |
Crizotinib |
| Drug ID |
BADD_D00535 |
| Description |
Crizotinib an inhibitor of receptor tyrosine kinase for the treatment of non-small cell lung cancer (NSCLC). Verification of the presence of ALK fusion gene is done by Abbott Molecular's Vysis ALK Break Apart FISH Probe Kit. This verification is used to select for patients suitable for treatment. FDA approved in August 26, 2011. |
| Indications and Usage |
Crizotinib is used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic-lymphoma kinase (ALK)-positive as detected by a FDA-approved test. |
| Marketing Status |
approved |
| ATC Code |
L01ED01 |
| DrugBank ID |
DB08865
|
| KEGG ID |
D09731
|
| MeSH ID |
D000077547
|
| PubChem ID |
11626560
|
| TTD Drug ID |
D03ZBT
|
| NDC Product Code |
68724-1020; 53869-2231; 53869-2230; 0069-8140; 0069-8141 |
| UNII |
53AH36668S
|
| Synonyms |
Crizotinib | PF-02341066 | PF-2341066 | PF 2341066 | PF2341066 | PF 02341066 | PF02341066 | Xalkori |
|
| Chemical Information |
| Molecular Formula |
C21H22Cl2FN5O |
| CAS Registry Number |
877399-52-5 |
| SMILES |
CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
